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Comprehensive Review
A systematic review and meta-analysis of the
prevalence of chronic widespread pain in the
general population
Kathryn E. Mansfielda,*, Julius Simb, Joanne L. Jordanb, Kelvin P. Jordanb
Abstract
Chronic widespread pain (CWP) is common and associated with poor general health. There has been no attempt to derive a robust
prevalence estimate of CWPor assess how this is influenced by sociodemographic factors. This study therefore aimed to determine,
through a systematic review and meta-analysis, the prevalence of CWP in the adult general population and explore variation in
prevalence by age, sex, geographical location, and criteria used to define CWP. MEDLINE, Embase, CINAHL, and AMED were
searched using a search strategy combining key words and related database-specific subject terms to identify relevant cohort or
cross-sectional studies published since 1990. Included articleswere assessed for risk of bias. Prevalence figures for CWP (American
College of Rheumatology criteria) were stratified according to geographical location, age, and sex. Potential sources of variation
were investigated using subgroup analyses and meta-regression. Twenty-five articles met the eligibility criteria. Estimates for CWP
prevalence ranged from 0% to 24%, with most estimates between 10% and 15%. The random-effects pooled prevalence was
10.6% (95% confidence intervals: 8.6-12.9). When only studies at low risk of bias were considered pooled, prevalence increased to
11.8% (95% confidence intervals: 10.3-13.3), with reduced but still high heterogeneity. Prevalence was higher in women and in
those agedmore than 40 years. Therewas some limited evidence of geographic variation and cultural differences. One in 10 adults in
the general population report chronic widespread pain with possible sociocultural variation. The possibility of cultural differences in
pain reporting should be considered in future research and the clinical assessment of painful conditions.
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1. Introduction
Chronic widespread pain (CWP) is a condition characterized by
long-standing diffuse musculoskeletal pain and frequently
associated with other physical symptoms such as fatigue,
psychological distress, and concentration problems. In the
American College of Rheumatology 1990 (ACR-1990) defini-
tion,43 CWP is the fundamental feature of fibromyalgia (FM) and is
defined as pain lasting 3months or longer, located axially (cervical
spine, thoracic spine, anterior chest, or low back), above and
below the waist, and on the left and right sides of the body.
In 2010, the ACR published an alternative set of criteria (ACR-
2010),41 meant to be used clinically, which emphasized the
importance of somatic symptoms (eg, fatigue,waking unrefreshed)
that have been associated with FM. The ACR-2010 criteria
dispensed with tender-point examination and instead used
a measure of the widespreadness of pain and a measure of the
number of somatic symptoms experienced, such as fatigue and
cognitive impairment. The new criteria place FM at one extreme on
a spectrum of polysymptomatic distress that includes CWP.
Although studies have reported the prevalence of CWP in
different populations, there has been no attempt to consolidate
these studies to derive a robust prevalence estimate of CWP or to
assess how this is influenced by sociodemographic factors. There
have been 3 systematic reviews and 2 narrative reviews of the
prevalence of “chronic pain,”12,30,31,34,38 and 1 study has
summarized the reported prevalence of CWP from 16 population
studies but was not a systematic review and did not attempt
a meta-analysis.27 Ascertaining the population prevalence of CWP
has important public health implications. It is difficult to justify and
plan interventions for conditions with an unknown community
burden. Furthermore, clinicians take into account estimates of
disease prevalence in different groups of the population (age, sex,
ethnicity) when formulating differential diagnoses. Investigating
how prevalence varies according to features such as age, sex, and
geographical location offers insights into possible aetiology.
We aimed to systematically review the existing literature that
presents estimates for CWP prevalence in the adult general
population. We chose to limit our review to studies using ACR
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criteria to define CWP to ensure that prevalence estimates were
comparable. The ACR-1990 criteria were selected as an
established and widely used measure of CWP diagnosis.
However, we also chose to include the more recent ACR-2010
criteria to investigate variation in prevalence based on the 2 ACR
CWP case definitions. We explored variation in prevalence
estimates by age, sex, and geographical location.
2. Methods
2.1. Eligibility criteria
All adult population-based (cross-sectional or cohort) studies
published since 1990where prevalence of CWPwas presented, or
could be calculated from available data, were considered for
inclusion. Only studies of CWP determined using either the ACR-
199043 or ACR-201041 CWP criteria were included. We excluded
studies that presented estimates based on specific subsets of
a general population (eg, women, hospital outpatient clinic
patients). However, we did not exclude some select populations
thatwere considered to be representative of the general population
in a particular geographical locale (eg, Pima Indians, Maori
population). Full inclusion and exclusion criteria are presented in
supplementary Table A1 (available online as Supplemental Digital
Content at http://links.lww.com/PAIN/A138).
2.2. Search strategy
MEDLINE, Embase, CINAHL, and AMED were searched up to
September 3, 2013 using a search strategy combining key words
and related database-specific subject terms. The search strategy
combined terms related to pain (chronic widespread pain, FM,
chronic pain syndrome, diffuse pain, fibrositis, fibromyositis,
myofascial pain) and terms related to study design (epidemiology,
cohort study, cohort analysis, cross-sectional study, cross-
sectional analysis, observational analysis, prevalence, disease
frequency) (supplementary Tables A2 and A3, available online as
Supplemental Digital Content at http://links.lww.com/PAIN/A138).
The titles of the articles returned were examined and any that
were obviously irrelevant were excluded. Abstracts and then full
text of the remaining articles were reviewed to find relevant
studies that met the inclusion criteria.
Additional relevant articles were identified by searching the
reference lists of full-text articles and hand-searching of the
Journal of Rheumatology (identified as the most frequent
contributor of articles in an initial scoping study). Native speakers
translated foreign language articles.
2.3. Risk of bias assessment
Articles included in the study were assessed for risk of bias using
2 domains of the Quality in Prognosis Studies tool16 that are
relevant to observational studies ([1] study participation and [2]
outcome measurement). Appraisal of each domain provides
a subjective assessment of risk of bias (ranked as low, moderate,
or high). A summary of the areas considered in the assessment of
each domain is included in the supplementary Table A4.1
(available online as Supplemental Digital Content at http://links.
lww.com/PAIN/A138).
2.4. Data extraction
A data extraction form was used to extract equivalent information
from each article. Information extracted included population
sampled, prevalence estimates, timeframe of prevalence esti-
mate (eg, point prevalence, annual prevalence), and any
prevalence estimates reported stratified by age, sex, or location.
The form also included fields to capture data relevant to the
assessment of risk of bias. Prevalence figures and 95%
confidence intervals (CIs) were extracted or calculated from the
available data using Wilson’s method.29
2.5. Reliability
Asecond reviewer (K.P.J.) blinded to theprimary reviewer’s (K.E.M.)
decisions checked the article selection, data extraction, and risk of
bias assessment stages of the review. In each instance, the number
of articles checked was the larger of either 10 studies or 10% of the
studies to be appraised. Any differences of opinionwere discussed,
and a third reviewer (J.S.) was available to arbitrate any issues that
remained unresolved.
2.6. Analysis
We undertook an initial descriptive analysis of the studies.
Heterogeneity between estimates was assessed using the I2
statistic, which describes the percentage of variation not because
of sampling error across studies. An I2 value above 75% indicates
high heterogeneity.18We limited the articles included in themeta-
analysis to those using the ACR-1990 criteria to define CWP.
Meta-analysis was undertaken using a random-effects model (to
account for heterogeneity) conducted using the MetaXL (www.
epigear.com) add-in for Microsoft Excel. A pooled prevalence
figure was calculated with 95% CI.
In ameta-analysis of prevalence, when the estimate for a study
tends towards either 0% or 100%, the variance for that study
moves towards zero and as a result its weight is overestimated in
the meta-analysis.5 Therefore, we conducted the meta-analysis
with prevalence estimates that had been transformed using the
double arcsine method.5 The final pooled result and 95% CIs
were back-transformed for ease of interpretation.
Potential influences on prevalence estimates were investi-
gated using subgroup analyses and meta-regression. Where
studies allowed, we descriptively compared prevalence
estimates by age, sex, and location within studies. We then
assessed the influence on estimates of the following study-
level variables identified a priori as potential sources of
variation in the estimates of prevalence: (1) risk of bias, (2)
geographical location, and (3) data collection method. We
classified studies as being either at low risk of bias (low risk of
both participation and outcome measurement bias) or at
moderate-to-high risk of bias (moderate or high risk of either
participation or outcome measurement bias). We also com-
pared European studies with North American studies. Data
collection method was assessed by comparing studies, where
data were collected by a self-completed questionnaire vs
a data collection method that required some form of human
interaction (eg, interview or telephone questionnaire). We ran 3
meta-regression models including these covariates separately
using Stata version 13.1.
3. Results
3.1. Search results
The search returned a total of 4051 publications, leading to 111
articles selected for full-text review. An additional 15 studies were
identified from the citation lists, and 1 further article,28 published
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after the formal database search had been completed, was
identified by an electronic citation alert for the ACR-1990 case
definition criteria.1 Hence, a total of 127 articles had their full-text
reviewed for inclusion. The screening process is detailed in
Figure 1.
One hundred and two articles were excluded after full-text
review. Twenty-five studies (reported in 28 articles)
1–4,6–11,13–15,19,20,22–26,28,32,33,35,37,39,40,42 were therefore
selected for inclusion in the review (Table 1), representing
37 CWP prevalence estimates.
3.2. Included studies
All studies included had a cross-sectional design and estimated
point prevalence. Twenty-four studies used ACR-1990 criteria,
and the remaining study defined CWP using the ACR-2010 criteria
of a widespread pain index of greater than or equal to 6 for
a minimum of 3 months.15 One study used an unstructured clinical
interview23 and the other 24 used a structured questionnaire. Of
the studies using a questionnaire, 102,6,10,13,19,25,28,32,37,42 used
a postal questionnaire, 51,3,8,35,39 used a telephone questionnaire,
39,20,22 used a face-to-face interview, 215,33 used a self-completed
questionnaire with help available from an interviewer if required,
and 411,14,24,40 used a mixture of self-completed questionnaires,
face-to-face interviews, and telephone questionnaires.
3.3. Risk of bias
A summary of the risk of bias of the included articles is provided in
Table 1; a justification of each rating is provided in the
supplementary appendix (Table A4.2, available online as Supple-
mental Digital Content at http://links.lww.com/PAIN/A138). Seven
studies (29%) were considered to be at low risk of bias for both
study participation and outcomemeasurement, and 2 studies (8%)
were considered to be at high risk of bias for both domains.
3.4. Study participation
Twenty-four percent (n5 6) of studies were considered to be at
high risk of study participation bias, 44% (n 5 11) were at
Figure 1. Flow chart to illustrate the process by which articles were selected or rejected for inclusion in the study.
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moderate risk, and 28% (n 5 7) at low risk (Table 1). One
study40 scored low risk of participation bias for one population
(Amish) under investigation and moderate risk for another (non-
Amish).
The main failings in sample selection were poor response
rates,1,23 nonrandom sampling of respondents,3,22,23 or re-
cruitment from a nonrepresentative sampling frame.11
The 7 studies at low risk of participation bias either selected
their study sample randomly or demonstrated that the sample
was representative of the study population. Response rates in the
low-risk studies were good or these studies were able to
demonstrate that the sample was representative of the pop-
ulation or that nonresponders were not significantly different from
responders.
3.5. Outcome measurement
Sixteen percent (n5 4) of the articles includedwere considered to
be at high risk of outcome measurement bias, 24% (n 5 6) at
moderate risk, and 60% (n 5 15) at low risk.
Four studies1,8,24,33 used nonrobust methods to establish
prevalence estimates. These prevalence figures were calculated
from data extrapolated from a subsample or from a nonrelated
population (eg, rheumatology outpatients) rather than from the
whole sample or the target population. Specifically, (1) 2
studies1,8 calculated a positive predictive value for a screening
questionnaire using data obtained from rheumatology out-
patients (number of confirmed ACR-1990-positive cases in those
identified as cases by the questionnaire) and used this to
Table 1
Summary of studies included and their risk of participation and outcome measurement bias.
Study Sample size Sample age Location and population Prevalence %
(95% CIs)
Risk of study
participation bias
Risk of outcome
measurement bias
Ablin et al.1 1019 181 Israel 5.1 (3.9-6.6)* High High
Aggarwal et al.2 2299 18-75 Manchester, United Kingdom 15.0 (12.3-16.5)* Low Low
Assumpc¸a˜o et al.3 768 35-60 Sa˜o Paulo, Brazil (low socioeconomic status) 24.0 (11.0-25.0) High Moderate
Bergman et al.6,7 2425 20-74 Sweden 11.4 (10.1-12.6) Low Low
Branco et al.4,8 4517 151 Five European countries 13.0 (12.0-14.0)* Moderate High
France 1014 France 10.0 (8.3-12.0)*
Italy 1000 Italy 10.0 (8.3-12.0)*
Germany 1002 Germany 11.0 (9.2-13.1)*
Portugal 500 Portugal 13.0 (10.3-16.2)*
Spain 1001 Spain 23.0 (20.5-25.7)*
Buskila et al.9 2210 181 Israel 10.2 (8.7-11.1) Low Low
Carnes et al.10 2445 181 South East, United Kingdom 12.0 (10.8-13.3)* Moderate Low
Choudhury et al.11 181 Tower Hamlets, London, United Kingdom High Moderate
Short postal survey 1223 Short postal survey
White British or Irish 571 White British or Irish 10.0 (2.0-18.0)
British Bangladeshi 141 British Bangladeshi 9.0 (0-25.0)
Bangladeshi 201 Bangladeshi 16.0 (3.0-28.0)
Other ethnic groups 310 Other ethnic groups 9.0 (0-20.0)
Long questionnaire 600 Long questionnaire
White British or Irish 294 White British or Irish 6.0 (0-18.0)
British Bangladeshi 158 British Bangladeshi 9.0 (0-24.0)
Bangladeshi 141 Bangladeshi 18.0 (3.0-33.0)
Croft et al.13 1340 18-85 Cheshire, United Kingdom 11.2 (9.6-13.0)* Low Low
Hardt et al.14 10,271 201 USA 3.6 (3.1-4.2) Moderate Moderate
Ha¨user et al.15,† 2510 141 Germany 5.8 (5.0-6.8)* Low Low
Hunt et al.19,26 1953 18-65 Manchester, United Kingdom (suburban) 12.9 (11.5-14.5) Low Low
Jacobsson et al.20 105 35-70 Pima Indians, Gila River Indian Community,
Phoenix, AZ, USA
0 (0-3.5) Moderate Moderate
Kim et al.22 1028 Not stated Gyeongsangbook-Do, South Korea 14.0 (12.0-16.2)* High Moderate
Klemp et al.23 689 121 New Zealand 2.8 (1.6-4.3) High Moderate
Lindell et al.24 147 18-74 Sweden 4.2 (3.4-5.0) High High
Macfarlane et al.25 18-75 United Kingdom Moderate Low
South Asian 1945 South Asian 13.8 (12.4-15.5)*
White European 932 White European 11.8 (9.9-14.0)*
Mundal et al.28 28,367 201 Norway 17.4 (16.9-17.8)* Moderate Low
Papageorgiou et al.32 1386 27-90 Handforth, United Kingdom 10.0 (8.6-11.7)* Low Low
Raspe and
Baumgartner33
438 25-74 Bad Sackingen, Germany 12.0 (9.4-15.5) Moderate High
Scudds et al.35 1467 18-65 Hong Kong 4.4 (3.4-5.5)* Moderate Low
Storozhenko et al.37 120 27-75 Yekaterinburg, Russia 13.3 (8.38-20.56)* Moderate Low
White et al.39 3395 181 London, ON, Canada (urban) 7.3 (6.5-8.2)*
White and Thompson40 181 Aylmer, ON, Canada
Amish 179 Amish 14.5 (10.1-20.4)* Low Low
Non-Amish (rural) 494 Non-Amish (rural) 8.9 (6.7-11.8)* Moderate Low
Wolfe et al.42 3006 181 Wichita, KS (urban) 10.6 (9.5-11.7) Moderate Low
Risk of bias assessed using Quality in Prognosis Studies (QUIPS) tool.16
* 95% confidence interval (CI) not presented in articles but calculated from sample size and prevalence estimate.
† Uses American College of Rheumatology (ACR)-2010 criteria of widespread pain index $6 for 3 months.
Studies presented with 2 references have results presented in both referenced papers. For convenience, in each instance only one of the papers has been named.
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calculate prevalence figures using the questionnaire responses
from the general population; (2) 1 study33 assumed an equal
frequency of CWP in responders and nonresponders and
extrapolated prevalence within responders to nonresponders to
calculate overall prevalence; and (3) 1 study24 calculated
prevalence based on examination of a stratified sample of
positive responders a year after their initial questionnaire re-
sponse. One article33 also failed to provide sufficient evidence of
validity of their data collection instrument.
The 15 studies at low risk of outcome measurement bias used
clearly defined diagnostic criteria, reliable and validated instru-
ments, and a similar method and setting of outcome measure-
ment for all participants.
3.6. Prevalence
Prevalence estimates ranged from 0% observed in a sample of
Pima Indians20 to 24% for low socioeconomic status populations
in Brazil.3 Most estimates were between 10% and 15% of the
population, and all the low-risk studies using ACR-1990 criteria
gave estimates between these 2 levels. There was greater
variation in studies with a high risk of bias.
Low estimates (less than 6%) were found in 7 stud-
ies.1,14,15,20,23,24,35 One study15 used the widespread pain index
from the ACR-2010 criteria to estimate a CWP prevalence of
5.8%. The remaining 6 low estimates came from studies using the
ACE-1990 criteria. One study24 used a slightly different applica-
tion of the case definition by using data from 2 different time
points a year apart; those with possible widespread pain were
identified by an initial postal questionnaire and followed up a year
later to identify CWP cases. Another study20 estimated preva-
lence in a particularly select population (Pima Indians). Three low
estimates1,23,35 were from studies at high risk of bias. The other
low estimate14 may be explained by data collection methods.
3.7. Sex variation
Fourteen articles presented prevalence figures by sex (Table 2).
Prevalence was higher for women in all studies; female-to-male
prevalence ratios ranged from 1.06 to 4.80, with most estimates
showing CWP prevalence in women to be around double that
observed in men.
3.8. Age variation
Theminimum age for the study population was 18 years or over in
all but 3 of the included studies.8,15,23 In these studies, the
minimum age was between 12 and 15 years, but estimates from
these 3 studies were within the range of those from studies with
minimum age of 18 years or over. Six studies presented age-
banded data (Fig. 2). These demonstrate an increase in CWP
prevalence to around age 40 to 50 and then either continually
increasing prevalence or a plateauing of prevalence estimates in
older age groups. Data from Croft et al.13 demonstrate 2 peaks:
one in middle age and another in old age.
3.9. Geographical variation
Figures for CWP in Europewere generally between 10%and 14%
(Table 3). One UK study25 observed higher prevalence in South
Asians than Europeans.
In North America, prevalence among the Amish was high at
14.5%, compared with 8.9% among rural Ontarians40 and 7.3%
among urban Ontarians.39 Pima Indians in Phoenix, Arizona, had
no observed CWP.20 The general population in the United States
was found to have a prevalence of 3.6% in a 2008 study14 and
10.6% in a 1995 study.42
Four11,23,25,40 studies made comparisons between different
ethnic or cultural groups resident in the same regions; all 4 studies
revealed appreciable differences in CWP prevalence.
3.10. Meta-analysis
Thirty-two prevalence estimates (from 23 articles) were included
in the meta-analysis. The 24 articles (36 prevalence estimates)
using ACR-1990 criteria to estimate CWP prevalence were
considered for entry and 4 estimates (from 2 articles) were
excluded. One estimate24 was excluded because the study
population was a subsample of those studied in another article.6
A further 3 estimates (from 1 article) were excluded to avoid
problems with overweighting a population; Choudhury et al.11
presented 7 prevalence estimates representing figures for
different ethnic groups from both a short postal survey and a long
questionnaire. Participants were recruited from the same
sampling frame, which could lead to overlap of study populations;
we therefore only included the estimates from the short postal
survey as the sample was more likely to be representative of the
general population.
The overall random-effects pooled prevalence of CWP was
10.6% (95% CIs: 8.6-12.9) with a high level of heterogeneity (I25
98.7%) (Fig. 3). When only studies at low risk of bias (on both
domains of the Quality in Prognosis Studies tool) were
considered, the pooled prevalence increased to 11.8 (95% CIs:
10.3-13.3), with reduced, but still high, heterogeneity (I2 5
85.1%). A sensitivity analysis using untransformed prevalence
estimates showed similar results.
The results of 3 meta-regression analyses including pooled
estimates for subgroups based on geographical location, risk of
bias, and data collection method are included in Table 4.
There was little evidence of an effect of data collection method
(P 5 0.181) or risk of bias (P 5 0.744) on prevalence. However,
there was an apparent higher prevalence in Europe than North
America (12.8% vs 7.1%, P 5 0.008).
4. Discussion
Twenty-five articles (37 prevalence estimates) were included in
this systematic review and meta-analysis of the prevalence of
CWP. Prevalence estimates of studies at low risk of bias were
between 10% and 15%. Pooled prevalence for studies at low risk
of bias was 11.8%. Prevalence was higher in women and in those
more than 40 years of age. There was some evidence of
geographic variation in prevalence between Europe and North
America. Some articles included in the review suggest that there
may be sociocultural variation in CWP.
The review searched 4 major bibliographic databases, using
a search strategy that had been tested in a pilot study, and we
translated all relevant foreign language articles. In addition, we
searched the citation lists of all articles selected for full-text review
and hand searched the Journal of Rheumatology for relevant
articles published after 1990. Moreover, at each step of the
identification and review process, a reliability exercise was
undertaken. However, we did not undertake a search of grey
literature, so there may be unpublished research that was not
included. Nonetheless, with such a large review of a topic, where
we could argue that any publication bias is unlikely to be
systematic, it seems reasonable to conclude that the included
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studies present a reasonable reflection of the true general
population prevalence of CWP.
A systematic review of tools to assess the quality of
observational studies examining incidence or prevalence36
concluded that no consensus exists as to which individual
criteria should be assessed to establish methodological quality.
The Cochrane Collaboration17 advise assessing risk of bias on
a subjective basis using domain-based evaluation. This advice
is also relevant to observational studies. Therefore, based on
an evaluation of different tools in a pilot study, we chose to use
a tool based on a subjective assessment of risk of bias in
separate domains.16 However, even guided by a tool, meth-
odological appraisal remains a subjective exercise. For this
reason, to minimize bias in the review process, for a random
sample of 10% of the included articles, 2 reviewers assessed
risk of bias independently, with minimal disagreement between
reviewers.
No effort was made to contact study authors for raw data. This
meant that, in some instances, 95% CIs for prevalence estimates
had to be calculated from information given in the article. It also
Table 2
Prevalence of chronic widespread pain in the adult general population, stratified by sex.
Study Prevalence % (95% CIs) Female:male ratio
Female Male
Kim et al.22 19.2 (16.4-22.4)* 4.0 (2.4-6.6)* 4.80
Buskila et al.9 14.0 (12.3-16.0) 3.0 (2.1-4.4) 4.67
Ablin et al.1 7.1 (5.2-9.7)* 3.0 (1.8-4.9)* 2.37
Bergman et al.6,7 15.3 (13.2-17.4) 7.5 (6.0-9.1) 1.76
Klemp et al.23 3.5 (1.9-5.8) 1.8 (1.0-4.1) 1.94
White et al.39 9.0 (7.8-10.2) 4.7 (3.5-5.8) 1.91
Carnes et al.10 14.4 (12.6-16.4)* 8.2 (6.7-10.0)* 1.76
Croft et al.13 15.6 (13.2-18.4)* 9.4 (7.3-12.1)* 1.66
Mundal et al.28 20.7 (20.1-21.4)* 12.8 (12.3-13.5)* 1.62
Aggarwal et al.2 16.0 (14.2-18.0)* 10.7 (8.9-12.6)* 1.50
Hardt et al.14 4.3 (3.5-5.3) 2.9 (2.3-3.7) 1.48
Storozhenko et al.37 14.6 (8.6-23.9)* 10.5 (4.2-24.1) 1.39
Ha¨user et al.15,† 6.3 (5.1-7.7)* 5.3 (4.2-6.7)* 1.19
White and Thompson (Amish)40 14.9 (9.2-23.1)* 14.0 (8.1-23.5)* 1.06
* 95% confidence interval (CI) not presented in articles but calculated from sample size and prevalence estimate.
† Uses American College of Rheumatology (ACR)-2010 criterion of widespread pain index $6 for 3 months.
Studies presented with two references have results presented in both referenced papers. For convenience, in each instance only one of the papers has been named.
Figure 2. Variation in chronic widespread pain prevalence (%) population by age. Note that the horizontal axes differ between graphs depending on the information
supplied in the corresponding reports.
60 K.E. Mansfield et al.·157 (2016) 55–64 PAIN®
  Copyright  2015 by the International Association for the Study of Pain. Unauthorized reproduction of this article is prohibited.
restricted the ability to assess the variability in prevalence
according to age. Of the articles that presented prevalence
figures according to age, the age groups used varied. Only 1
study reported prevalence based on the ACR-2010 criteria;
hence, we were unable to assess variation between the 2 ACR
criteria definitions.
Given the varied methodological approaches of the studies
included in the review, the appropriateness of calculating
pooled prevalence estimates could be questioned. Given high
heterogeneity between studies, the pooled prevalence estimate
should therefore be interpreted with caution. However, only
studies using the ACR-1990 case definition criteria were
entered the meta-analysis, and these criteria were selected as
an established and widely used standard for CWP and FM
diagnosis. Including studies using the same diagnostic criteria in
similar populations (male and female adults) ensured some
comparability. The heterogeneity in pooled prevalence esti-
mates may have been due to data collection method, the
geographical location of the study, or bias introduced by study
methods. The impact of study quality on pooled prevalence was
assessed by systematically excluding low-quality studies and
studies examining particularly select populations from themeta-
analysis and by conducting a meta-regression comparing
studies at low risk of bias with those at moderate-to-high risk.
Meta-regression demonstrated little evidence of data collection
method or higher risk of bias giving a consistently higher or lower
level of prevalence.
The prevalence estimates of low-risk studies were consis-
tently between 10% and 15%. Prevalence estimates in females
were around double those for males, whereas prevalence
Table 3
Prevalence of chronic widespread pain in the adult general population (%), stratified by geographical location.
Geographical region Study Population Prevalence % (95% CIs)
Asia Scudds et al.35 Hong Kong (Chinese population) 4.4 (3.4-5.5)*
Kim et al.22 Gyeongsangbook-Do, South Korea 14.0 (12.0-16.2)*
Australasia Klemp et al.23 New Zealand 2.8 (1.6-4.3)
Middle East Buskila et al.9 Israel 10.2 (8.7-11.1)
Ablin et al.1 Israel 5.1 (3.9-6.6)*
South America Assumpc¸a˜o et al.3 Sao Paulo, Brazil (low socioeconomic status) 24.0 (21.0-27.0)
North America
Canada White and Thompson40
Amish ON, Canada (Amish) 14.5 (10.1-20.4)*
Non-Amish (rural) ON, Canada (rural, non-Amish) 8.9 (6.7-11.8)*
White et al.39 London, ON, Canada (urban) 7.3 (6.5-8.2)*
USA Jacobsson et al.20 Pima Indians, Gila River, AZ 0 (0-3.5)
Hardt et al.14 USA 3.6 (3.1-4.2)
Wolfe et al.42 USA 10.6 (9.5-11.7)
Europe
Central and Western Europe Papageorgiou et al.32 Handforth, United Kingdom 10.0 (8.6-11.7)*
Croft et al.13 Cheshire, United Kingdom 11.2 (9.6-13.0)*
Carnes et al.10 South East, United Kingdom 12.0 (10.8-13.3)*
Choudhury et al.11 East London, United Kingdom
Short postal survey White British or Irish 10.0 (2.0-18.0)
British Bangladeshi 9.0 (0-25.0)
Bangladeshi 16.0 (3.0-28.0)
Other ethnic groups 9.0 (0-20.0)
Long questionnaire White British or Irish 6.0 (0-18.0)
British Bangladeshi 9.0 (0-24.0)
Bangladeshi 18.0 (3.0-33.0)
Hunt et al.19,26 Manchester, United Kingdom 12.9 (11.5-14.5)
Macfarlane et al.25 Bolton, Oldham, Aston, Tameside, and
Birmingham, United Kingdom
White European 11.8 (9.9-14.0)*
South Asian 13.8 (12.4-15.5)*
Aggarwal et al.2 Manchester, United Kingdom 15.0 (12.3-15.1)*
Raspe and Baumgartner33 Bad Sackingen, Germany 12.0 (9.4-15.5)
Ha¨user et al.15,† Germany 5.8 (5.0-6.8)*
Branco et al.4,8 Europe 13.0 (12.0-14.0)*
France 10.0 (8.3-12.0)*
Italy 10.0 (8.3-12.0)*
Germany 11.0 (9.2-13.1)*
Portugal 13.0 (10.3-16.2)*
Spain 23.0 (20.5-25.7)*
Scandinavia Lindell et al.24 Halmstad & Laholm, Sweden 4.2 (3.4-5.0)
Bergman et al.6,7 Halmstad & Laholm, Sweden 11.4 (10.1-12.6)
Mundal et al.28 Norway 17.4 (16.9-17.8)*
Russia Storozhenko et al.37 Yekaterinburg, Russia 13.3 (8.38-2.56)*
* 95% CI not presented in articles but calculated from sample size and prevalence estimate.
† Uses American College of Rheumatology (ACR)-2010 criterion of widespread pain index $6 for 3 months.
CI, confidence interval.
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estimates generally plateaued in middle age (40-60 years). This
matches the patterns of prevalence of primary care-recorded
widespread pain consultation21 and nonspecific chronic pain.38
European estimates of prevalence were slightly higher than
those from North America. However, the number of North
American studies was low and only 2 of these 6 studies were not
in more specific populations. Smaller numbers of studies from
other locations and diverse methodological approaches make
comparisons between other regions difficult. There were some
apparent cultural and socioeconomic differences in CWP
Figure 3. Forest plot of prevalence (%) of American College of Rheumatology (ACR)-1990 chronic widespread pain of studies. Subgrouped by risk of bias.
Random-effects analysis. (A) Low-risk studies are those at low risk of bias on both domains of Quality in Prognosis Studies (QUIPS) tool. (B) Intermediate-risk studies
are those at eithermoderate risk of bias onboth domains ormoderate risk in one and low in the other. (C)High-risk studies are those at high risk of bias oneither domain
of the QUIPS tool. (D) Select populations: Pima Indians,20 Amish population,40 white European, and South Asian.25 SQ, short postal questionnaire. Studies presented
with two references have results presented in both referenced papers. For convenience, in each instance only one of the papers has been named.
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prevalence. The 2 most extreme outliers for CWP prevalence
included in the review represent select populations (considered to
be representative of the general population in the geographical
locale from which they were selected) rather than the wider
general population. The highest estimate for prevalence is for
a low socioeconomic population,3 whereas the lowest estimate is
in a North American Indian trial population.20
Four11,23,25,40 studies found differences in CWP prevalence
between ethnic or cultural groups. Although observed differences
in prevalence in 2 of these studies may also be due to different
approaches to data collection40 and recruitment,23 this findingmay
offer some support for ethnic or cultural variation in CWP.Whether
any differences in the experience of CWP are attributable to
lifestyle, genetics, or sociocultural influences are unclear, and it is
difficult to draw convincing conclusions based on evidence from
only 4 studies. However, potential cultural differences in pain
reporting should be considered during clinical history taking, and
further research should investigate the extent and nature of ethnic,
cultural, and regional variation inCWPprevalence, as thismay offer
insights into the aetiology or management of this condition.
5. Conclusions
Chronic widespread pain is a common problem, reported by 1 in
10 adults, with prevalence twice as high in women as in men and
with those aged more than 40 having a higher prevalence.
Heterogeneity between studies made assessment of geograph-
ical variation difficult. However, there may be cultural differences
in CWP prevalence, and the possibility of such differences in pain
reporting should be considered in future research and the clinical
assessment of painful conditions.
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